23 July 2015
EMA/495872/2015
Press Office

Start of community reviews

CHMP meeting of 20-23 July 2015

Table 1. Start of reviews for centrally authorised medicines

Name	INN	Type of procedure	Scope
InductOs	dibotermin alfa	Article 20 of Regulation (EC) 726/2004	Procedure triggered by the European Commission following the final GMP non-compliance statement being issued for the manufacturer of one of the components of Inductos (the absorbable sponge). No risks for the patient associated to this issue have been identified. The EMA's Committee for Medicinal Products for Human Use (CHMP) will now review the impact of the inspection findings, that led to the withdrawal of the GMP certificate, on the product's overall benefits and risks and make a recommendation as to whether any changes are needed to its marketing authorisation.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact